文献速递银屑病与炎症性皮肤病

司库奇尤单抗持续治疗与高维持或重获应答相关

Continued treatment with secukinumab is associated with high retention or regain of response.
PubMed 文献 · Br J Dermatol · 2019-07-17

本文为FIXTURE与CLEAR两项III期随机对照试验的事后分析,在个体患者层面评估司库奇尤单抗治疗中重度银屑病52周内应答稳定性。多数患者疗效稳定,部分应答下降者继续治疗后可重获应答,持续性应答丧失不常见。

要点

  • 司库奇尤单抗52周内多数患者疗效稳定,持续性应答丧失不常见。
  • 部分应答下降患者继续司库奇尤单抗治疗后可重获应答。
  • 体重等患者因素可能影响应答丧失的可能性。

核心结论

  • 司库奇尤单抗治疗52周内多数患者疗效稳定,继续治疗可使部分应答下降患者重获疗效,持续性应答丧失不常见。

研究设计与样本

  • FIXTURE(NCT01358578)与CLEAR(NCT02074982)两项III期随机对照试验的事后分析。
  • 患者接受司库奇尤单抗300 mg(FIXTURE和CLEAR)、依那西普50 mg(FIXTURE)或乌司奴单抗45或90 mg(CLEAR),疗程52周。
  • 应答按互斥类别定义:PASI 90为「优」、PASI 75且<PASI 90为「良」、<PASI 75为「不足」。
  • 疗效下降定义为连续两次访视间由高类别降至低类别并在第三次连续访视维持。
  • 疗效丧失定义为疗效下降至「不足」应答;所有比较均为描述性。

主要发现

  • CLEAR中52周时90·2%(303/336)的司库奇尤单抗患者达到无丧失的稳定疗效,77·7%(261/336)无任何应答下降。
  • CLEAR中乌司奴单抗患者相应比例为74·3%(252/339)和59·9%(203/339)。
  • FIXTURE中83·5%(273/327)的司库奇尤单抗患者无丧失,66·4%(217/327)无应答下降。
  • FIXTURE中依那西普患者相应比例为58·3%(190/326)和42·6%(139/326)。
  • 继续司库奇尤单抗治疗重获应答者CLEAR为50%(8/16)、FIXTURE为26%(9/34)。

关键数值与推荐

  • 稳定疗效无丧失:CLEAR司库奇尤单抗90·2%(303/336)、乌司奴单抗74·3%(252/339)。
  • 稳定疗效无任何应答下降:CLEAR司库奇尤单抗77·7%(261/336)、乌司奴单抗59·9%(203/339)。
  • 稳定疗效无丧失:FIXTURE司库奇尤单抗83·5%(273/327)、依那西普58·3%(190/326)。
  • 稳定疗效无任何应答下降:FIXTURE司库奇尤单抗66·4%(217/327)、依那西普42·6%(139/326)。
  • 继续治疗重获应答:CLEAR 50%(8/16)、FIXTURE 26%(9/34)。

临床怎么用

  • 对司库奇尤单抗治疗中应答下降的患者,可考虑继续治疗以争取重获应答。
  • 评估疗效稳定性时应关注个体患者层面的应答类别变化,而非仅看汇总数据。
  • 体重等患者因素可能影响应答丧失风险,需在随访中加以关注。

局限性

  • 本文为两项III期试验的事后分析,所有比较均为描述性。
  • 应答下降与丧失的定义基于访视间类别变化,可能受评估间隔影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Conventional analyses present aggregate data, masking late responders and efficacy reductions. Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin (IL)-17A, shows sustained efficacy in moderate-to-severe psoriasis. OBJECTIVES: To determine stability of response to secukinumab, changes in efficacy were assessed in individual patients. METHODS: This is a post hoc analysis of two phase III randomized controlled trials, FIXTURE (trial registration: NCT01358578) and CLEAR (trial registration: NCT02074982). Patients received secukinumab 300 mg (FIXTURE and CLEAR), etanercept 50 mg (FIXTURE) or ustekinumab 45 or 90 mg (CLEAR) over 52 weeks. Mutually exclusive response categories were defined: ≥ 90% improvement in the Psoriasis Area and Severity Index (PASI 90) ('excellent'), ≥ 75% improvement in PASI (PASI 75) and < PASI 90 ('good') and < PASI 75 ('insufficient'). Reductions in efficacy were defined as shifts from higher to lower response categories between two consecutive visits maintained for a third consecutive visit. Loss of efficacy was defined as a reduction of efficacy resulting in 'insufficient' response. All comparisons are descriptive. RESULTS: At 52 weeks, in CLEAR, 90·2% (303/336) of patients on secukinumab achieved stable efficacy without loss and 77·7% (261/336) showed stable efficacy without any reduction of response [74·3% (252/339) and 59·9% (203/339) of patients for ustekinumab]. In FIXTURE, 83·5% (273/327) and 66·4% (217/327) of patients on secukinumab had stable efficacy without loss or reduction of response [58·3% (190/326) and 42·6% (139/326) for etanercept]. Response was regained by continuing secukinumab treatment in 50% (8/16) of patients in CLEAR and 26% (9/34) in FIXTURE. Similar patterns were observed for other response definitions. CONCLUSIONS: Efficacy with secukinumab was stable over 52 weeks of treatment in most patients. Continued treatment with secukinumab resulted in regain of efficacy in some patients. Persistent loss of response was uncommon. What's already known about this topic? Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin (IL)-17A, shows significant and sustained efficacy in the treatment of moderate-to-severe psoriasis. Secondary loss of response may be experienced by a minority of patients treated with secukinumab, as with other biologics, but the extent of this and the potential for regain of efficacy with continued treatment is not well understood. What does this study add? To determine stability of response to secukinumab and inform clinical practice, changes in efficacy were assessed at individual patient level using response categories. Efficacy with secukinumab was stable over 52 weeks of treatment in most patients, and continued treatment with secukinumab resulted in efficacy regain after loss in some patients. Persistent loss of response was uncommon. Patient factors such as body weight may affect the likelihood of loss of efficacy.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Augustin M, Thaci D, Eyerich K, et al. Continued treatment with secukinumab is associated with high retention or regain of response. Br J Dermatol. 2019. PMID: 30972746. doi:10.1111/bjd.17991

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。